Search results
Here's Why Eli Lilly Stock Remains a Screaming Buy
Motley Fool via Yahoo Finance· 14 minutes agoLilly expects to file for U.S. approval of the drug in treating heart failure with preserved ejection fraction (HFpEF) later this year. ...Zepbound are,...
Trending tickers: Shell, Apple, Novo Nordisk and Standard Chartered
Yahoo Finance UK· 43 minutes agoNordisk (NOVO-B.CO) Europe’s most-valuable company revealed better-than-expected profits for the...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 3 hours agoLast year, major pharmaceutical companies heavily invested in R&D, with expenditure ranging from around 14% to 50% of their revenues. Some...expenditure...
Some of the popular weight loss drug Wegovy is back on shelves after a shortage, the FDA says
Quartz· 3 days agoA dose of Wegovy’s highly-coveted weight loss drug is no longer in limited supply, according to Food...
DEA will move to reclassify marijuana as a less-dangerous drug
San Jose Mercury News· 2 days agoThe U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug,...
London Drugs closes stores after cyber incident
Supermarket News· 15 hours agoThe cybersecurity incident was the second breach at a major North American healthcare company in recent months following an attack in February at Change...
Why Cannabis Companies Tilray, Canopy Growth, Cronos, and SNDL Got Really High on Tuesday
Motley Fool via Yahoo Finance· 2 days agoBut perhaps the most onerous headwind that will be reversed by rescheduling is...companies will no...
Dow Jones Futures Rise, Carvana Skyrockets; Stock Market Erases Fed Gains
Investor's Business Daily· 5 hours agoNVO stock edged up 0.7% Wednesday to 129.21, just above the 50-day. The weight-loss drug giant has a...
These Are the Drugs America Is Running Short On
247wallst.com· 3 days agoDrug shortages in America are the result of supply line challenges, profit-based operations, and company closures.
Schrodinger Inc (SDGR) Q1 2024 Earnings Call Transcript Highlights: A Mixed Start with ...
GuruFocus.com via Yahoo Finance· 2 hours agoThe company's gross margin declined to 52% in Q1 2024 from 71% in Q1 2023, driven by lower drug discovery revenue. Q & A Highlights Q: Can you discuss the ...
